Back to Journals » Cancer Management and Research » Volume 7

Expanding role of lenalidomide in hematologic malignancies

Authors Ghosh N, Grunwald M, Fasan O, Bhutani M

Received 21 January 2015

Accepted for publication 10 March 2015

Published 2 May 2015 Volume 2015:7 Pages 105—119


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Kenan Onel

Video abstract presented by Nilanjan Ghosh

Views: 414

Nilanjan Ghosh, Michael R Grunwald, Omotayo Fasan, Manisha Bhutani

Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA

Abstract: Lenalidomide is an immunomodulatory agent that has been approved by the US Food and Drug Administration for treatment of multiple myeloma, deletion 5q myelodysplastic syndrome, and mantle cell lymphoma. In addition, it has clinical activity in lymphoproliferative disorders and acute myeloid leukemia. The mode of action includes immunomodulatory, anti-inflammatory, antiangiogenic, and antiproliferative mechanisms. The antitumor effect is a result of direct interference of key pathways in tumor cells and indirect modulation of the tumor microenvironment. There has been no recent collective review on lenalidomide in multiple myeloma, myelodysplastic syndrome/acute myeloid leukemia, and lymphoma. This review summarizes the results of current clinical studies of lenalidomide, alone and in combination with other agents, as a therapeutic option for various hematologic malignancies.

Keywords: IMiD, leukemia, lymphoma, myeloma, MDS

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]